Surgical Outcomes of Perioperative Durvalumab in AEGEAN Study to be Presented at IASLC 2023 World Conference on Lung Cancer

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI TDS Source Type: news